Depomed to Present at the CIBC World Markets Healthcare Conference
Posted on: Wednesday, 2 November 2005, 09:01 CST
Depomed, Inc. (NASDAQ:DEPO) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., will present on Wednesday, November 9, 2005 at 9:00 a.m. Eastern Time during the CIBC World Markets Healthcare Conference.
Interested parties can access a live, or archived, Internet broadcast of the presentation at http://conferences.cibcwm.com/health05/ (webcast source code: november). The presentation will be archived for 30 days.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative Gastric Retention (GR) system to develop novel oral products and improved, extended release formulations of existing oral drugs. GR-based products are designed to provide once daily administration and reduced gastrointestinal side effects, improving patient convenience, compliance and pharmacokinetic profiles. Proquin(R) XR (ciprofloxacin hydrochloride) once daily, extended-release tablets have been approved by the FDA for the treatment of uncomplicated urinary tract infections. In addition, regulatory applications for once daily Glumetza(TM) (Metformin GR(R)) for the treatment of Type II diabetes have been approved in the U.S. and Canada. The company is also conducting a Phase II trial in post herpetic neuralgia with their product, Gabapentin GR(TM). Additional information about Depomed may be found at its web site, www.depomedinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Source: Business Wire
Related Articles
- ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
- Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
- Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
- ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
- Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an Investigational Population, Patients Previously Untreated for HIV-1
- FDA Approves Once-Daily Veramyst(TM) (Fluticasone Furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children As Young As Two Years
- Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral Multiple Sclerosis Therapy FTY720 (Fingolimod) Published in New England Journal of Medicine
- Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD
- Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy
- Multimedia News Release - RAZADYNE(TM) ER, New Once-Daily Treatment Option, Now Available for Patients With Mild to Moderate Alzheimer's Disease
 |
 |
User Comments (0)
RSS Feeds